SAB BIOTHERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
SAB BIOTHERAPEUTICS, INC. (SABS) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Amount of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherAdjustments · last filed 2026-03-09
- SAB BIOTHERAPEUTICS, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2025 was $0.00.
- SAB BIOTHERAPEUTICS, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2024 was -$339.17K.
- SAB BIOTHERAPEUTICS, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2023 was -$452.45K.
- SAB BIOTHERAPEUTICS, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2022 was -$24.68K.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-09 | |
| 2024-12-31 | -$339.17K 10-K · filed 2026-03-09 | |
| 2023-12-31 | -$452.45K 10-K · filed 2025-03-31 | |
| 2022-12-31 | -$24.68K 10-K · filed 2024-03-29 | -$866.39K 10-K · filed 2023-04-14 |
| 2021-12-31 | -$98.91K 10-K/A · filed 2023-04-28 | |
| 2020-12-31 | $1.00 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |